Palo Alto Investors’s Travere Therapeutics TVTX Stock Holding History

Palo Alto Investors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.85M	Buy	230,453 +119,734	+108%	+$3.58M	1.05%	26
2025 Q4	$4.23M	Hold	110,719	–	–	0.59%	32
2025 Q3	$2.65M	Hold	110,719	–	–	0.49%	30
2025 Q2	$1.64M	Hold	110,719	–	–	0.35%	33
2025 Q1	$1.98M	Hold	110,719	–	–	0.38%	28
2024 Q4	$1.93M	Hold	110,719	–	–	0.3%	29
2024 Q3	$1.55M	Hold	110,719	–	–	0.2%	32
2024 Q2	$910K	Hold	110,719	–	–	0.11%	34
2024 Q1	$854K	Hold	110,719	–	–	0.1%	35
2023 Q4	$995K	Sell	110,719 -55,350	-33%	-$403K	0.09%	30
2023 Q3	$1.48M	Hold	166,069	–	–	0.14%	24
2023 Q2	$2.55M	Hold	166,069	–	–	0.21%	22
2023 Q1	$3.73M	Hold	166,069	–	–	0.31%	20
2022 Q4	$3.49M	Hold	166,069	–	–	0.3%	21
2022 Q3	$4.09M	Hold	166,069	–	–	0.32%	24
2022 Q2	$4.02M	Hold	166,069	–	–	0.35%	25
2022 Q1	$4.28M	Hold	166,069	–	–	0.33%	24
2021 Q4	$5.16M	Hold	166,069	–	–	0.33%	25
2021 Q3	$4.03M	Hold	166,069	–	–	0.24%	29
2021 Q2	$2.42M	Hold	166,069	–	–	0.13%	32
2021 Q1	$4.15M	Buy	166,069 +8,169	+5%	+$226K	0.24%	29
2020 Q4	$4.3M	Hold	157,900	–	–	0.23%	25
2020 Q3	$2.92M	Buy	157,900 +110,900	+236%	+$2.16M	0.16%	28
2020 Q2	$959K	Hold	47,000	–	–	0.06%	35
2020 Q1	$686K	Buy	+47,000	New	+$707K	0.06%	30

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Palo Alto Investors's TVTX Position: Q1 2026 in Review

Palo Alto Investors increased its Travere Therapeutics (TVTX) stake by 108% in Q1 2026, buying an estimated $3.58M and bringing the position to 230,453 shares worth $6.85M. The position accounts for 1.05% of the portfolio, ranked #26.

Palo Alto Investors first reported a position in TVTX in Q1 2020 and has held it in 25 quarters since. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Palo Alto Investors held 230,453 shares of Travere Therapeutics worth $6.85M as of Q1 2026.
Palo Alto Investors bought 119,734 Travere Therapeutics shares in Q1 2026, an estimated $3.58M.
Travere Therapeutics made up 1.05% of Palo Alto Investors's portfolio in Q1 2026, its #26 holding.
Palo Alto Investors first reported a position in Travere Therapeutics in Q1 2020 and has held it in 25 quarters since.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Palo Alto Investors's 13F filing for Q1 2026, filed 15 May 2026.